Recent Media Coverage

	BioMedReports.com
September 2010	CEL-SCI's Multikine Back in the Spotlight BioMedReports.com is a website for healthcare investors and traders with a blog, discussion forum, stock research reports, news feeds, videos, stock commentaries, and a database of pending FDA new product decisions and clinical trial results which are organized in a calendar format.

	NOVATEK International
April 2010	CEL-SCI Goes Live with Novatek's Environmental Monitoring LIMS Software (NOVA-EM) Since 1996, Novatek International has been providing a new breed of all-encompassing, process-driven LIMS software solutions that target the pharmaceutical, biotech and other health-care industries.

Technology Review

November
24, 2009

Arming the Immune System against H1N1: Researchers are working to treat pandemic flu by recruiting a patient's own immune cells.

Technology Review and Technologyreview.com are published by Technology Review Inc., an independent media company owned by the Massachusetts Institute of Technology. The oldest technology magazine in the world (est. 1899), Technology Review aims to promote the understanding of emerging technologies and to analyze their commercial, social, and political impacts.

	Investment U
October 7, 2009	The Next Big Thing In Health Care: How to Profit From Immunotherapy & Regenerative Medicine Founded in 1999, the goal of Investment U is to give you impartial, no-nonsense advice on how to build long-lasting wealth. Our mission is to analyze and discuss all the important financial tools at your disposal.

	Washington Business Journal
September 16, 2009	CEL-SCI to begin H1N1 treatment trial

	BioMedReports.com
September 16, 2009	CEL-SCI's Positive Perfect Storm
September 16, 2009	CEL-SCI's New H1N1 Treatment Granted Expedited Review by FDA
September 14, 2009	Cloak and Dagger Developments at CEL-SCI

	Richmond Times-Dispatch
September 2, 2009	Virginia Economy: Let's Be Sure Biotech Has a Bright Future Op Ed by Geert Kersten, CEO of CEL-SCI Corporation

	BioMedReports.com
August 25, 2009	Filing wih the SEC Makes CEL-SCI's Plans Look Even More Enticing to Investors
August 21, 2009	CEL-SCI's CEO feeling bullish after key developments
July 30, 2009	Biotech Drug Company Preparing for Worst Case H1N1 Flu Scenario Using Extremely Promising New Technology
July 30, 2009	Who's Afraid of the Big Bad Flu? One company is diligently preparing for the worst case scenario with promising results.

	Washington Business Journal
August 20, 2008	Cel-Sci lets Teva sell cancer drug

Med Ad News - Cover Story

February
2008

Eighth Annual Report: Future Blockbusters

These 10 medicines are expected to eventually garner FDA approval and break the annual billion-dollar sales barrier.

Med Ad News is the leading source of information on the business and marketing activities of the pharmaceutical industry. Published monthly, Med Ad News has become a standard throughout the pharmaceutical industry for its coverage of news, articles, special features and annual reports. Med Ad News is distributed to and read by more than 15,000 pharmaceutical professionals. It is the most respected and authoritative publication serving the pharmaceutical industry today. Posted with permission from Med Ad News, February 2008

Click here to read a transcript of the article.

Khaleej Times, United Arab Emirates

January
28, 2008

CEL-SCI Corporation targets Gulf investors

Click here to read a transcript of the article.

Emirates Business 24/7, United Arab Emirates

January
28, 2008

US firm seeks funding for cancer treatment

Click here to read a transcript of the article.

Trade Arabia , On-line

January
28, 2008

New immune boosting drug to treat cancer